Stay updated on Denosumab with Checkpoint Inhibitors in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Denosumab with Checkpoint Inhibitors in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Denosumab with Checkpoint Inhibitors in Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8, indicating a modification in the study plan for the evaluation of Denosumab in combination with immune checkpoint inhibitors in patients with unresectable or metastatic melanoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:17:42.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of what eligibility criteria entail, including examples such as a person's general health condition or prior treatments.
    Difference
    50%
    Check dated 2024-05-22T20:58:44.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:54:51.000Z thumbnail image

Stay in the know with updates to Denosumab with Checkpoint Inhibitors in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Denosumab with Checkpoint Inhibitors in Melanoma Clinical Trial page.